Kopran Ltd Share Price
As on 19 November 2025 at 02:58 IST
Kopran Ltd. Q1 FY26 Results:
Profit for the period declined 33% to ₹7.4 crores in Q1 FY26, from ₹11.1 crores in Q1 FY25. Total income for the quarter decreased 3% year-on-year to ₹138 crores, from ₹142 crores.
About Kopran Ltd
Kopran Ltd is an integrated pharmaceutical company engaged in the manufacture and marketing of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates in the healthcare sector, specifically within the pharmaceuticals and drugs industry. Kopran Ltd was incorporated in the year 1958, making it decades old in its field. The headquarters of Kopran Ltd is in Worli, Mumbai, Maharashtra, India. Kopran Ltd's main products include a wide range of pharmaceutical formulations and APIs. The company's product portfolio covers various therapeutic categories, including macrolide, antibacterial, gastroenterology, and cardiovascular drugs. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-16.11%
Over 6 Months
-25.10%
Over 1 Year
-37.72%
Over 3 Years
-6.43%
Kopran Ltd Summary
Close ₹139.33
Open ₹142.99
High ₹143.45
Low ₹139
Volume 1,86,039
Net Turnover (in Cr) ₹2.62
52Wk High ₹235.90
52Wk Low ₹139
52Wk High / Low
139
235.90
Kopran Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹672.76
EPS (TTM) 3.22
Book Value (BV) 86.21
Div. Yield 2.15 %
P/E (TTM) 43.34
Price/Book Value 1.62
Delivery % 61.25 %
Face Value 10
Key Ratios
PE Ratio 31.49
PB Ratio 1.96
EV to Sales 3.21
PEG Ratio -1.40
ROA 5.57
ROE 6.33
Debt-Equity 0.08
Net Profit Margin 9.91
Operating Profit Margin 16.44
Kopran Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 633.59 | 629.20 | 554.05 | 488.13 | 509.80 |
| Total Expenses | 581.64 | 561.66 | 517.99 | 406.35 | 426.46 |
| Profit Before Tax | 51.95 | 67.54 | 36.07 | 81.78 | 83.34 |
| Profit After Tax | 38.55 | 50.96 | 27.23 | 61.03 | 61.61 |
| Operating Profit After Depreciation | 61.29 | 76.14 | 42.15 | 86.90 | 89.57 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 222.22 | 200.65 | 178.91 | 158.69 | 118 |
| Total Non Current Assets | 334.26 | 289.22 | 250.63 | 196.01 | 162.43 |
| Total Current Assets | 509.75 | 454.03 | 399.07 | 414.87 | 276.95 |
| Total Assets | 844.01 | 743.25 | 649.70 | 610.89 | 439.38 |
| Total Shareholder's Fund | 518.35 | 491.25 | 439.25 | 426.17 | 245.03 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 41.94 | 43.26 | 34.02 | -33.48 | 59.95 |
| Net Cash Used In Investing Activities | -56.43 | -43.55 | -12.65 | -84.42 | -25.28 |
| Net Cash Used In Financing Activities | 25.87 | 0.99 | -19.84 | 122.82 | -34.57 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 276.91 | 354.17 | 289.18 | 212.55 | 233.25 |
| Total Expenses | 241.12 | 309.65 | 252.27 | 196.38 | 200.54 |
| Profit Before Tax | 35.79 | 44.52 | 36.92 | 16.16 | 32.71 |
| Profit After Tax | 26.86 | 34.64 | 31.25 | 11.74 | 23.47 |
| Operating Profit After Depreciation | 39.56 | 49.02 | 39.59 | 19.12 | 36.51 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 66.78 | 56.72 | 50.88 | 49.32 | 50.26 |
| Total Non Current Assets | 337.44 | 323.17 | 315.54 | 312.81 | 212.84 |
| Total Current Assets | 209.05 | 187.70 | 190.41 | 151.31 | 111.12 |
| Total Assets | 546.48 | 510.88 | 505.95 | 464.12 | 323.95 |
| Total Shareholder's Fund | 431.44 | 416.87 | 395.59 | 378.72 | 246.85 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 23.30 | 34.96 | 16.87 | -37.80 | 48.77 |
| Net Cash Used In Investing Activities | -15.41 | -6.27 | 10.05 | -100.26 | -8.51 |
| Net Cash Used In Financing Activities | 5.64 | -24.08 | -26.13 | 137.99 | -40.14 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 117.91 | 135.22 | 172.36 | 166.24 | 151.56 |
| Total Expenses | 123.19 | 121.08 | 155.28 | 146.40 | 136.83 |
| Profit Before Tax | -11.62 | 9.90 | 13.70 | 13.85 | 9.65 |
| Profit After Tax | -9.92 | 7.45 | 9.68 | 10.40 | 7.38 |
| Operating Profit after Depreciation | -5.25 | 16.70 | 20.34 | 20.01 | 15.73 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 42.39 | 51.33 | 75.94 | 71.94 | 73.53 |
| Total Expenses | 45.60 | 46.26 | 63.65 | 60.54 | 63.84 |
| Profit Before Tax | -4.88 | 4.61 | 11.71 | 9.83 | 8.75 |
| Profit After Tax | -3.99 | 3.52 | 8.60 | 7.41 | 6.60 |
| Operating Profit after Depreciation | -2.89 | 6.87 | 14.21 | 12.15 | 10.81 |
Kopran Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 137.74
S2 136.14
S3 133.29
Pivot 140.59
R1 142.19
R2 145.04
R3 146.64
Moving Average
20 SMA 160.85
50 SMA 169.60
100 SMA 169.92
200 SMA 177.01
Kopran Ltd Corporate Actions
Kopran Ltd
₹3.0/Share
Announcement Date 04 Sep 2025
Record Date 04 Sep 2025
Div Yield 30%
Kopran Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,763.70 | ₹4,23,170.71 |
| Divis Laboratories Ltd | ₹6,523.25 | ₹1,73,171.79 |
| Torrent Pharmaceuticals Ltd | ₹3,816.75 | ₹1,29,170.36 |
| Cipla Ltd | ₹1,536.25 | ₹1,24,093.85 |
| Dr Reddys Laboratories Ltd | ₹1,244.50 | ₹1,03,868.61 |
Kopran Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Bandhan BSE Healthcare Index Fund | 0.03% |
Kopran Ltd News
Kopran to conduct board meeting
On 12 November 2025
31 Oct 2025, 10:14 am
Kopran Ltd Spurts 4.13%
Kopran Ltd has lost 8.09% over last one month compared to 0.96% fall in BSE Healthcare index and 0.54% drop in the SENSEX
19 Aug 2025, 09:30 am
Kopran to hold AGM
On 11 September 2025
31 Jul 2025, 09:15 am
Kopran to table results
On 29 July 2025
19 Jul 2025, 10:03 am
Board of Kopran recommends final dividend
Of Rs 3 per share
15 May 2025, 04:01 pm
Kopran Ltd Stock Analysis
- Annual revenue for Kopran Ltd decreased by 21.81% to ₹276.91 crore in FY 2025 from ₹354.17 crore in FY 2024.
- Annual Net Profit for Kopran Ltd decreased by 22.46% to ₹26.86 crore in FY 2025 from ₹34.64 crore in FY 2024.
- Promoter Shareholding in Kopran Ltd remains unchanged by 0.00% in the most recent quarter, from 44.42% in June 2025 to 44.42% in September 2025.
- Kopran Ltd delivered a 1-year return of -37.72% compared to the Nifty 50, which provided a return of 10.91% as of the last trading session.
- Kopran Ltd share price moved down by 1.03% from its previous close of INR ₹139.33. The latest Kopran Ltd share price is INR ₹137.90.
- Kopran Ltd share price today has been at a low of 137.17 and a high of 140.35. Over the past 52 weeks, the Kopran Ltd share price has seen a low of 137.17 and a high of 235.90.
About Kopran Ltd
Kopran Ltd is an integrated pharmaceutical company engaged in the manufacture and marketing of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates in the healthcare sector, specifically within the pharmaceuticals and drugs industry. Kopran Ltd was incorporated on April 26, 1958, making it decades old in its field.
The headquarters of Kopran Ltd is in Worli, Mumbai, Maharashtra, India. The key promoters of the company include Oricon Enterprises Ltd, with a 12.89% stake. Susheel G Somani serves as the Chairman of the company, supported by a team of managerial promoters who oversee its operations. They are-
Additionally, Kopran Ltd provides drugs for erectile dysfunction, antiallergics, and respiratory conditions. Its portfolio also includes medications for oncology, antiprotozoal, anti-peptic ulcer, and gut health. The company is not the biggest player in its industry. However, it does hold a notable position in its sector.
The registered office of Kopran Ltd is in Worli, Mumbai. Meanwhile the office of the registrars is in Pinnacle Business Park, Mumbai. Overall, Kopran Ltd is an integrated pharmaceutical company with decades of experience. It excels in the manufacture and marketing of APIs and finished dosage forms. Despite not being the largest player, its commitment to quality has made it a significant entity in the industry, helping it gain trust and credibility in the market.
Innovation is at the heart of Kopran Ltd's vision. The company is dedicated to developing new and advanced pharmaceutical products. Its focus is on meeting the evolving needs of patients and healthcare providers. Research and development are key components of Kopran Ltd's strategy. The company invests significantly in advanced facilities and cutting-edge technologies. These efforts enable the company to stay ahead of industry trends and deliver innovative solutions that improve health outcomes.
Quality is another cornerstone of Kopran Ltd's vision. The company is committed to maintaining the highest standards of quality across all its products and processes. Rigorous quality control measures are implemented at every stage of production, from sourcing raw materials to manufacturing and packaging finished products. This focus on quality ensures that Kopran Ltd's products are safe and reliable. As a result, it has earned the trust and confidence of customers and healthcare professionals.
Customer satisfaction is a key element for the goal Kopran Ltd wants to achieve. The company strives to understand and meet the needs of its customers, both in terms of product offerings and service delivery. This customer-centric approach helps Kopran Ltd build strong relationships with its clients and maintain a loyal customer base.
The vision of Kopran Ltd includes a commitment to global expansion. The company aims to extend its reach beyond the Indian market and establish a strong presence in international markets. Strategic partnerships and collaborations with global pharmaceutical companies are pursued to achieve this objective.
Employee development is another key component of Kopran Ltd's vision. The company acknowledges that its employees are its greatest asset. It is committed to providing them with opportunities for growth and development. Comprehensive training programs, mentorship opportunities, and a supportive work environment are offered. These initiatives help employees reach their full potential. This investment in human capital not only enhances employee satisfaction and retention but also contributes to the overall success of the company.
Kopran Ltd's vision also includes a focus on ethical business practices. The company adheres to the highest standards of integrity and transparency in all its dealings. Ethical considerations are also factored into every decision, ensuring that the company's actions align with its values. This commitment to ethics has earned Kopran Ltd a strong reputation in the industry and has helped build trust with stakeholders.
The goal of Kopran Ltd is centred around innovation and ethical business practices. These guiding principles help the company maintain its leadership in the pharmaceutical industry. They also enable it to continue making a positive impact on society. Kopran Ltd's unwavering commitment to its vision drives its actions and decisions, positioning it for long-term success and growth.
Global expansion is a key objective for Kopran Ltd. The company aims to establish a strong presence in international markets through strategic partnerships and collaborations. Employee development is also a priority, with comprehensive training programs and mentorship opportunities provided to support employee growth and development.
Ethical business practices are a cornerstone of Kopran Ltd's vision, ensuring that the company's actions align with its values and build trust with stakeholders. This commitment to ethics has earned Kopran Ltd a strong reputation in the industry.
Overall, the vision of Kopran Ltd is a comprehensive and multifaceted strategy that guides the company's actions and decisions. Innovation, global expansion, employee development, and ethical business practices are the core principles that drive Kopran Ltd's success. By adhering to its vision, Kopran Ltd continues to make a positive impact on society and remains a leader in the pharmaceutical industry.
The headquarters of Kopran Ltd is in Worli, Mumbai, Maharashtra, India. The key promoters of the company include Oricon Enterprises Ltd, with a 12.89% stake. Susheel G Somani serves as the Chairman of the company, supported by a team of managerial promoters who oversee its operations. They are-
- Surendra Somani
- Adarsh Somani
- Varun Somani
- Siddhan Subramanian
Additionally, Kopran Ltd provides drugs for erectile dysfunction, antiallergics, and respiratory conditions. Its portfolio also includes medications for oncology, antiprotozoal, anti-peptic ulcer, and gut health. The company is not the biggest player in its industry. However, it does hold a notable position in its sector.
The registered office of Kopran Ltd is in Worli, Mumbai. Meanwhile the office of the registrars is in Pinnacle Business Park, Mumbai. Overall, Kopran Ltd is an integrated pharmaceutical company with decades of experience. It excels in the manufacture and marketing of APIs and finished dosage forms. Despite not being the largest player, its commitment to quality has made it a significant entity in the industry, helping it gain trust and credibility in the market.
The Vision of Kopran Ltd
Kopran Ltd is a well-established pharmaceutical company with a clear and ambitious vision. The goal of Kopran Ltd revolves around several core principles, including innovation, quality, and customer satisfaction. These principles guide the company's actions and decisions, ensuring that it remains a leader in the pharmaceutical industry.Innovation is at the heart of Kopran Ltd's vision. The company is dedicated to developing new and advanced pharmaceutical products. Its focus is on meeting the evolving needs of patients and healthcare providers. Research and development are key components of Kopran Ltd's strategy. The company invests significantly in advanced facilities and cutting-edge technologies. These efforts enable the company to stay ahead of industry trends and deliver innovative solutions that improve health outcomes.
Quality is another cornerstone of Kopran Ltd's vision. The company is committed to maintaining the highest standards of quality across all its products and processes. Rigorous quality control measures are implemented at every stage of production, from sourcing raw materials to manufacturing and packaging finished products. This focus on quality ensures that Kopran Ltd's products are safe and reliable. As a result, it has earned the trust and confidence of customers and healthcare professionals.
Customer satisfaction is a key element for the goal Kopran Ltd wants to achieve. The company strives to understand and meet the needs of its customers, both in terms of product offerings and service delivery. This customer-centric approach helps Kopran Ltd build strong relationships with its clients and maintain a loyal customer base.
The vision of Kopran Ltd includes a commitment to global expansion. The company aims to extend its reach beyond the Indian market and establish a strong presence in international markets. Strategic partnerships and collaborations with global pharmaceutical companies are pursued to achieve this objective.
Employee development is another key component of Kopran Ltd's vision. The company acknowledges that its employees are its greatest asset. It is committed to providing them with opportunities for growth and development. Comprehensive training programs, mentorship opportunities, and a supportive work environment are offered. These initiatives help employees reach their full potential. This investment in human capital not only enhances employee satisfaction and retention but also contributes to the overall success of the company.
Kopran Ltd's vision also includes a focus on ethical business practices. The company adheres to the highest standards of integrity and transparency in all its dealings. Ethical considerations are also factored into every decision, ensuring that the company's actions align with its values. This commitment to ethics has earned Kopran Ltd a strong reputation in the industry and has helped build trust with stakeholders.
The goal of Kopran Ltd is centred around innovation and ethical business practices. These guiding principles help the company maintain its leadership in the pharmaceutical industry. They also enable it to continue making a positive impact on society. Kopran Ltd's unwavering commitment to its vision drives its actions and decisions, positioning it for long-term success and growth.
Global expansion is a key objective for Kopran Ltd. The company aims to establish a strong presence in international markets through strategic partnerships and collaborations. Employee development is also a priority, with comprehensive training programs and mentorship opportunities provided to support employee growth and development.
Ethical business practices are a cornerstone of Kopran Ltd's vision, ensuring that the company's actions align with its values and build trust with stakeholders. This commitment to ethics has earned Kopran Ltd a strong reputation in the industry.
Overall, the vision of Kopran Ltd is a comprehensive and multifaceted strategy that guides the company's actions and decisions. Innovation, global expansion, employee development, and ethical business practices are the core principles that drive Kopran Ltd's success. By adhering to its vision, Kopran Ltd continues to make a positive impact on society and remains a leader in the pharmaceutical industry.
FAQ’s
What is the share price of Kopran Ltd today?
Kopran Ltd share price as on 18 Nov 2025 is ₹ 137.9
What is the Market Cap of Kopran Ltd?
The market cap of Kopran Ltd stock is ₹672.76 Cr.
What is the PE Ratio of Kopran Ltd?
The Price to Earnings (P/E) Ratio of Kopran Ltd is 31.49
What is the PB Ratio of Kopran Ltd?
The Price to Book (P/B) Ratio of Kopran Ltd is 1.96
What is the 52 week high of Kopran Ltd Share Price?
The 52 week high of Kopran Ltd share price stands at ₹235.90
What is the 52 week low of Kopran Ltd Share Price?
The 52 week low of Kopran Ltd share price stands at ₹139
How can I buy shares of Kopran Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Kopran Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
